- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jacob Ballon Discusses the Opportunity to Use Big Data to Identify Types of Psychotic Illnesses
Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University, explained how large databases can help researchers understand the variety of psychotic illnesses, potentially leading to more personalized treatments.
Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University, explained how large databases can help researchers understand the variety of psychotic illnesses, potentially leading to more personalized treatments.
Transcript
How could we potentially leverage the power of big data and technology to better treat or prevent psychosis?
There’s a great opportunity in looking at big data to be able to better appreciate the heterogeneity of different disorders. Schizophrenia is not just simply 1 thing, and as we are able to utilize large data sets, whether it’s through genomics or other -omics, or through treatment outcomes through Medicaid databases or other large databases, we’ll be able to hopefully parse out exactly what are the different types of psychotic illnesses that people have, to better tailor treatment and hopefully achieve more personalized medicine.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
